MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of debt
$99,965K
Proceeds from exercise of
stock options
$1,606K
Net cash provided by
financing activities
$101,446K
Canceled cashflow
$125K
Net decrease in cash
-$28,376K
Canceled cashflow
$101,446K
Stock-based compensation
expense
$11,138K
Depreciation and
amortization
$2,483K
Accretion of debt discount
and non-cash...
$2,439K
Non-cash lease expense
$1,803K
Prepaid expenses and
other current assets
-$1,400K
Accounts receivable
-$200K
Receivables from related
parties
-$23K
Other receivables
-$20K
Loss on disposal of
property and equipment
-$12K
Proceeds from the sale of
property and equipment
$3K
Payment of third-party
fees associated with...
$125K
Net cash used in
operating activities
-$129,794K
Canceled cashflow
$19,518K
Net cash used in
investing activities
-$28K
Canceled cashflow
$3K
Net income (loss)
-$140,055K
Accrued expenses
-$4,361K
Accounts payable
-$3,301K
Operating lease liability
-$1,595K
Purchase of property and
equipment
$31K
Back
Back
Cash Flow
source: myfinsight.com
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)